Please login to the form below

Not currently logged in
Email:
Password:

Yervoy

This page shows the latest Yervoy news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The combination of Opdivo and Yervoy lies at the heart of much of Bristol-Myers Squibb’s ambition in immuno-oncology, and an FDA approval for the pairing in kidney cancer ... BMS notes that Opdivo and Yervoy was given a priority review by the FDA last

Latest news

More from news
Approximately 30 fully matching, plus 120 partially matching documents found.

Latest Intelligence

  • Pharma deals in February 2015 Pharma deals in February 2015

    As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.

  • Pharma deals during July 2014 Pharma deals during July 2014

    In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics